KALARX.COM: Keyword Density Checker

Total words: 1305 | 2-word phrases: 341 | 3-word phrases: 375 | 4-word phrases: 388

PAGE INFO

Title	Try to keep the title under 60 characters (19 characters) About Us - KALA BIO
Description	Try to keep the meta description between 50 - 160 characters (0 characters)
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (68 characters) KALA BIO is a clinical-stage biopharmaceutical company on a mission.

#	Keyword	Frequency	Density
1	the treatment of	4	1.07%
2	bio is a	3	0.80%
3	kala bio is	3	0.80%
4	rare ocular surface	3	0.80%
5	etabonate ophthalmic suspension	2	0.53%
6	we are developing	2	0.53%
7	for rare ocular	2	0.53%
8	for the treatment	2	0.53%
9	ocular surface diseases	2	0.53%
10	kpi012 has received	2	0.53%
11	has received orphan	2	0.53%
12	received orphan drug	2	0.53%
13	orphan drug and	2	0.53%
14	fast track designation	2	0.53%
15	from the fda	2	0.53%
16	the fda for	2	0.53%
17	as the first	2	0.53%
18	to support bla	2	0.53%
19	trials to support	2	0.53%
20	required trials to	2	0.53%
21	two required trials	2	0.53%
22	of two required	2	0.53%
23	first of two	2	0.53%
24	the first of	2	0.53%
25	serve as the	2	0.53%
26	could serve as	2	0.53%
27	phase 2b study	2	0.53%
28	current phase 2b	2	0.53%
29	the current phase	2	0.53%
30	from the current	2	0.53%

#	Keyword	Frequency	Density
1	kala bio is a	3	0.77%
2	the first of two	2	0.52%
3	could serve as the	2	0.52%
4	for the treatment of	2	0.52%
5	rare ocular surface diseases	2	0.52%
6	trials to support bla	2	0.52%
7	kpi012 has received orphan	2	0.52%
8	has received orphan drug	2	0.52%
9	received orphan drug and	2	0.52%
10	required trials to support	2	0.52%
11	two required trials to	2	0.52%
12	first of two required	2	0.52%
13	as the first of	2	0.52%
14	from the fda for	2	0.52%
15	the fda for pced	2	0.52%
16	serve as the first	2	0.52%
17	of two required trials	2	0.52%
18	the treatment of rare	2	0.52%
19	for rare ocular surface	2	0.52%
20	the current phase 2b	2	0.52%
21	from the current phase	2	0.52%
22	results from the current	2	0.52%
23	positive results from the	2	0.52%
24	current phase 2b study	2	0.52%
25	degenerations and other back	1	0.26%
26	of of inherited retinal	1	0.26%
27	treatment of of inherited	1	0.26%
28	the treatment of of	1	0.26%
29	geneagnostic approach for the	1	0.26%
30	sightthreatening diseases bla biologics	1	0.26%
31	approach for the treatment	1	0.26%
32	other back of the	1	0.26%
33	a geneagnostic approach for	1	0.26%
34	preclinical development to provide	1	0.26%
35	in preclinical development to	1	0.26%
36	and other back of	1	0.26%
37	lives of patients with	1	0.26%
38	back of the eye	1	0.26%
39	of the eye diseases	1	0.26%
40	of patients with rare	1	0.26%

#	URL	Whois	Check
1	https://www.linkedin.com/company/kala-pharmaceuticals/	Whois	linkedin.com